FedEx shareholders voted down a plan to make the company report on legal risks tied to shipping abortion pills, but the fight over who controls what rides inside a delivery truck is far from over.
Story Snapshot
- A shareholder proposal asked FedEx to study legal and reputational risks from shipping mail-order abortion drugs like mifepristone.
- Stockholders rejected the proposal at FedEx’s September 28 annual meeting, with reports showing roughly 1.1% in favor and 96.4% against.
- FedEx says it is only a carrier, not a manufacturer, distributor, prescriber, or dispenser of drugs.
- Backers point to the Comstock Act, an old federal law some say bans carriers from shipping abortion-inducing drugs, as a legal risk FedEx hasn’t fully addressed.
Faith-Backed Investors Push FedEx on Abortion Drug Shipping
IWP Capital, working with the Catholic Diocese of Fort Worth, filed a shareholder proposal asking FedEx’s board to study the risks of shipping abortion drugs. The proposal, titled “Report on Risks Related to Distributing Abortion Drugs,” appeared in FedEx’s 2026 proxy statement. It asked for a report within one year, at reasonable cost, on legal, regulatory, and reputational dangers tied to transporting drugs like mifepristone through the mail.
Pia de Solenni, IWP Capital’s vice president of corporate engagement, said FedEx’s role moving regulated products could create real exposure. She argued that hauling packages containing mifepristone and other abortion drugs could expose the company to “legal and reputational risks”. The proposal did not demand FedEx stop shipping anything. It simply asked the board to study the problem and report back to investors.
FedEx Draws a Clear Line on Its Role
FedEx pushed back hard on the premise behind the proposal. The company said it is “a transportation and logistics provider, not a manufacturer, distributor, prescriber, or dispenser of pharmaceutical products”. FedEx added that it moves regulated goods under existing laws, regulations, and customer agreements, and its board said the company already has “robust risk management” systems that handle these questions without a special report.
The board told shareholders the proposal wasn’t practical and wouldn’t be a good use of company resources given its wide scope. That response shows FedEx leadership sees this less as a moral question and more as a business one: a matter of liability, resources, and staying out of a political fight that isn’t theirs to referee.
Comstock Act Looms Over the Debate
Supporters of the proposal leaned on a 19th-century law called the Comstock Act. According to meeting transcripts, the law “prohibits the use of any express company or common carrier to transport any drug or medicine designed, adapted, or intended for producing abortion”. That old statute has become a flashpoint in today’s abortion fights, with some legal scholars arguing it could apply to modern shipping companies even though it has rarely been enforced that way in recent decades.
No court has ruled that FedEx’s shipping practices violate the Comstock Act, and no lawsuit or government enforcement action against the company has surfaced publicly. That gap matters. It means the risk described in the proposal is legal theory, not a proven violation, even as it raises real questions corporate boards nationwide may eventually have to answer.
Shareholders Reject the Measure by a Wide Margin
When the vote came at FedEx’s annual meeting on September 28, investors turned down the proposal decisively. Reported results show about 1.1% voted in favor, while 96.4% voted against it. That lopsided outcome was one of three stockholder proposals rejected that day, alongside measures on board leadership and special-meeting rights, suggesting broad investor reluctance to wade into contested social issues through corporate governance votes.
Today's Early Word:
⁉️ Mystery retailer buys Ikea
⛳️ Audubon's clubhouse tees off
💊 Abortion pill debate enters FedEx boardroom
🚓 Crime by the numbershttps://t.co/XajBM4ubwW— The Daily Memphian (@DailyMemphian) September 30, 2026
The low vote total doesn’t settle the underlying argument, though. Pro-life investors say the company is ignoring a risk hiding in plain sight, pointing to shipping volume and a disputed legal theory as reasons for caution. FedEx and most of its shareholders say the company is a neutral carrier following the law, not a decision-maker on what medicine gets made or prescribed. Both sides agree on one thing: the fight over who bears responsibility when lawful commerce brushes against deeply divisive laws isn’t going away soon.
Sources:
ground.news, dailymemphian.com, es.tradingview.com, stocktitan.net, morningstar.com
